We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients.
Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis
SPANEVELLO, ANTONIO;
2009-01-01
Abstract
We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Journal of Antimicrobial Chemotherapy (2009) Sotgiu.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
68.89 kB
Formato
Adobe PDF
|
68.89 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
